retatrutide glp-1 gip glucagon agonist Synedica Beyond GLP-1: Retatrutide's triple-agonist mechanism

Human trials have not started as of late 2025, but the preclinical data is promising

However, not enough private insurers were willing to participate, so instead CMS is running an 18-month demonstration project (Bridge), where the obesity drugs are covered directly by the taxpayers and future Medicare premiums

Canadian researchers report average body composition changes of 15-25 pounds of fat loss combined with 8-15 pounds of lean mass gain over 12-16 week protocols

Our holistic approach, guided by experienced healthcare providers, ensures that every client receives a customized plan tailored to their medical history, current health status, and specific objectives

If you or a loved one has been adversely affected by GLP-1 RAs, experienced Shreveport products liability lawyer Joey Greenwald is here to help

The weight loss was a fortuitous side effect because semaglutide was originally designed to be a treatment for diabetes